9 research outputs found
Baseline characteristics of children prescribed different asthma controller medications.
<p>
<i>ICS =  Inhaled corticosteroid; LTRA = leukotriene receptors antagonists; LABA/ICS =  fixed dose long-acting β2 -agonist and inhaled corticosteroids combination; LABA+ICS =  concurrent long-acting β2 -agonist and inhaled corticosteroids separate inhaler; SCSIMD  =  Scottish Index of Multiple Deprivation; SABA =  Short-acting β2–agonist; OCS =  Oral corticosteroids.</i></p
Adjusted<sup>*</sup> odds ratios of being prescribed reliever medications for children with adequate versus inadequate MPR, stratified by controller medication.
*<p>
<i>Adjusted for age, gender, socio-economic status and pre index prescribing of asthma medications. Adjusted OR = Adjusted odds ratios; SABA = Short-acting β2–agonist; OCS = Oral corticosteroids; ICS = Inhaled corticosteroid; LTRA = leukotriene receptors antagonists; LABA/ICS = fixed dose long-acting β2-agonist and inhaled corticosteroids combination; LABA+ICS = concurrent long-acting β2 -agonist and inhaled corticosteroids separate inhaler.</i></p
The relationship between reliever medication prescription in the post index year and the medication possession ratio.
<p>
<i>% of children with adequate vs inadequate MPR. e.g. x% of children with adequate MPR had an OCS prescription while xx% of those with inadequate MPR had an OCS prescription.</i></p>*<p>
<i>P<0.001;</i></p>**<p>
<i>P<0.05.</i></p><p>
<i>SABA =  Short-acting β2–agonist; OCS =  Oral corticosteroids; ICS =  Inhaled corticosteroid; LTRA = leukotriene receptors antagonists; LABA/ICS =  fixed dose long-acting β2 -agonist and inhaled corticosteroids combination; LABA+ICS =  concurrent long-acting β2 -agonist and inhaled corticosteroids separate inhaler.</i></p
Adequate MPR for asthma controller medications by deprivation index, age and gender.
*<p>
<i>P<0.001; ICS =  Inhaled corticosteroid; LTRA = leukotriene receptors antagonists; LABA/ICS =  fixed dose long-acting β2 -agonist and inhaled corticosteroids combination; LABA+ICS =  concurrent long-acting β2 -agonist and inhaled corticosteroids separate inhaler; SCSIMD  =  Scottish Index of Multiple Deprivation.</i></p
Box plot for the distribution of Medication Possession Ratio of prescribed asthma controller medications.
<p>Whiskers represent the extreme values, and boxes represent the 75th quartile, median, and 25th quartile. Outliers were excluded from the analysis. MPR =  Medication possession ratio; ICS = Inhaled corticosteroid; LTRA = leukotriene receptors antagonists; LABA/ICS = fixed dose long-acting β2-agonist and inhaled corticosteroids combination; LABA+ICS =  concurrent long-acting β2-agonist and inhaled corticosteroids separate inhaler.</p
Survival function for all-cause longer term (31 days to 5 years) mortality after first acute myocardial infarction by age group (n = 2104).
<p>Survival function for all-cause longer term (31 days to 5 years) mortality after first acute myocardial infarction by age group (n = 2104).</p
Factors affecting longer-term (31 days to 5 years) mortality (N = 2104).
*<p>p<0.05;</p>†<p>p<0.01;</p>‡<p>p<0.001.</p><p>CHD = coronary heart disease; CKD = chronic kidney disease; PVD = peripheral vascular disease; AF = atrial fibrillation.</p
Co-morbidity of patients receiving revascularization or secondary preventive therapy (yes vs. no).
<p>Co-morbidity of patients receiving revascularization or secondary preventive therapy (yes vs. no).</p
The effect of coronary revascularization procedures and secondary prevention therapy during follow-up (as time-varying covariates) on longer-term (31 days to 5 years) mortality.
*<p>Adjusted for baseline characteristics and all time varying covariates.</p>†<p>p<0.05;</p>‡<p>p<0.01;</p>§<p>p<0.001.</p><p>ACE = angiotensin converting enzyme; AMI = acute myocardial infarction; CHD = coronary heart disease; CABG = coronary artery bypass grafting; PTCA = percutaneous transluminal coronary angioplasty.</p